News
Article
Author(s):
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
A recent study reveals a significant link between alopecia areata severity and increased risk of atopic dermatitis, especially in adolescents.
FDA enhances transparency by publishing over 200 Complete Response Letters, offering insights into drug approval processes and common deficiencies.
Christopher Bunick, MD, PhD, highlights how dupilumab transforms atopic dermatitis treatment in children, improving health outcomes and quality of life beyond skin symptoms.
Zelsuvmi is the first FDA-approved at-home treatment for molluscum contagiosum, now available for patients aged ≥1 via retail and mail-order pharmacies.
A pilot study evaluates tildrakizumab's safety and potential in treating stable non-segmental vitiligo, highlighting the need for further research on IL-23 inhibitors.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.